Cystoid Macular Edema Arising 10 Years After Cessation of Pentosan Polysulfate Sodium Successfully Treated With Bevacizumab

Overview

Journal J Vitreoretin Dis

Publisher Sage Publications

Date 2023 Apr 3

PMID 37008392

Authors

Jason T Szelog

Neil S Shah

M David Camejo

Affiliations

Soon will be listed here.

Abstract

Purpose: To describe a patient initially diagnosed with age-related macular degeneration (AMD) who was ultimately determined to have progressing pentosan polysulfate sodium (PPS)-associated maculopathy leading to secondary cystoid macular edema (CME) 10 years after cessation of PPS.

Methods: An interventional case report is presented.

Results: A 57-year-old woman diagnosed with AMD presented with unilateral worsening vision and metamorphopsia from CME. A detailed history showed a 3-year course of PPS, which had been discontinued 10 years previously. This led to the diagnosis of PPS-associated maculopathy. After topical NSAID and corticosteroid treatment failed, intravitreal bevacizumab resolved the symptoms. CME developed in the fellow eye 5 months later and also responded to bevacizumab.

Conclusions: This case emphasizes the importance of a thorough review of past medication and medical histories in patients with pigmentary retinopathy and supports the use of antivascular endothelial growth factor therapy as an option to treat CME secondary to PPS-associated maculopathy.

References

Hanif A, Shah R, Yan J, Varghese J, Patel S, Cribbs B . Strength of Association between Pentosan Polysulfate and a Novel Maculopathy. Ophthalmology. 2019; 126(10):1464-1466. DOI: 10.1016/j.ophtha.2019.04.024. View

De Larochelliere E, Bourgault S . PENTOSAN POLYSULFATE SODIUM-INDUCED PIGMENTARY MACULOPATHY WITH NONLEAKING CYSTOID MACULAR EDEMA SUCCESSFULLY TREATED WITH ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY. Retin Cases Brief Rep. 2020; 16(4):482-485. DOI: 10.1097/ICB.0000000000001013. View

Barnett J, Jain N . POTENTIAL NEW-ONSET CLINICALLY DETECTABLE PENTOSAN POLYSULFATE MACULOPATHY YEARS AFTER DRUG CESSATION. Retin Cases Brief Rep. 2020; 16(6):724-726. DOI: 10.1097/ICB.0000000000001090. View

Hanif A, Armenti S, Taylor S, Shah R, Igelman A, Jayasundera K . Phenotypic Spectrum of Pentosan Polysulfate Sodium-Associated Maculopathy: A Multicenter Study. JAMA Ophthalmol. 2019; 137(11):1275-1282. PMC: 6735406. DOI: 10.1001/jamaophthalmol.2019.3392. View

Barnes A, Hanif A, Jain N . Pentosan Polysulfate Maculopathy versus Inherited Macular Dystrophies: Comparative Assessment with Multimodal Imaging. Ophthalmol Retina. 2020; 4(12):1196-1201. DOI: 10.1016/j.oret.2020.05.008. View

Wang D, Au A, Gunnemann F, Hilely A, Scharf J, Tran K . Pentosan-associated maculopathy: prevalence, screening guidelines, and spectrum of findings based on prospective multimodal analysis. Can J Ophthalmol. 2020; 55(2):116-125. DOI: 10.1016/j.jcjo.2019.12.001. View

Pearce W, Chen R, Jain N . Pigmentary Maculopathy Associated with Chronic Exposure to Pentosan Polysulfate Sodium. Ophthalmology. 2018; 125(11):1793-1802. DOI: 10.1016/j.ophtha.2018.04.026. View

Vora R, Patel A, Yang S, Melles R . A case of pentosan polysulfate maculopathy originally diagnosed as stargardt disease. Am J Ophthalmol Case Rep. 2020; 17:100604. PMC: 6997837. DOI: 10.1016/j.ajoc.2020.100604. View

Mishra K, Patel T, Singh M . Choroidal Neovascularization Associated with Pentosan Polysulfate Toxicity. Ophthalmol Retina. 2019; 4(1):111-113. DOI: 10.1016/j.oret.2019.08.006. View

10.

Vora R, Patel A, Melles R . Prevalence of Maculopathy Associated with Long-Term Pentosan Polysulfate Therapy. Ophthalmology. 2020; 127(6):835-836. DOI: 10.1016/j.ophtha.2020.01.017. View

11.

Abou-Jaoude M, Davis A, Fraser C, Leys M, Hinkle D, Odom J . New Insights Into Pentosan Polysulfate Maculopathy. Ophthalmic Surg Lasers Imaging Retina. 2021; 52(1):13-22. DOI: 10.3928/23258160-20201223-04. View